Fisher Asset Management LLC Has $179.72 Million Position in Pfizer Inc. (NYSE:PFE)

Fisher Asset Management LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 226.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,209,907 shares of the biopharmaceutical company’s stock after buying an additional 4,309,076 shares during the quarter. Fisher Asset Management LLC owned about 0.11% of Pfizer worth $179,715,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Daiwa Securities Group Inc. grew its position in shares of Pfizer by 25.9% during the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company’s stock worth $23,283,000 after buying an additional 165,611 shares during the period. Marco Investment Management LLC grew its position in shares of Pfizer by 3.6% during the 3rd quarter. Marco Investment Management LLC now owns 148,432 shares of the biopharmaceutical company’s stock worth $4,296,000 after buying an additional 5,100 shares during the period. Hartford Funds Management Co LLC grew its position in shares of Pfizer by 5.7% during the 3rd quarter. Hartford Funds Management Co LLC now owns 31,832 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 1,716 shares during the period. Pekin Hardy Strauss Inc. grew its position in shares of Pfizer by 3.0% during the 3rd quarter. Pekin Hardy Strauss Inc. now owns 27,895 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 800 shares during the period. Finally, Westfield Capital Management Co. LP grew its position in shares of Pfizer by 21.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 335,556 shares of the biopharmaceutical company’s stock worth $9,711,000 after buying an additional 60,378 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 2.0 %

Shares of Pfizer stock opened at $26.17 on Tuesday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a market cap of $148.31 billion, a P/E ratio of 35.37, a P/E/G ratio of 0.82 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $28.13 and its 200-day moving average is $28.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.17) EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.42%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.